The organizations have long collaborated on recommendations for critical steps to improve the nation's supply chain and mitigate drug shortages, including a summit in July 2020 that examined the resilience of the U.S. pharmaceutical supply chain in light of the current state of global pharmaceutical manufacturing. The group is asking policymakers to implement a range of legislative and regulatory actions, including:

Incentivize advanced manufacturing technology and develop new continuous manufacturing technology for critical drugs and active pharmaceutical ingredients. The group recommends legislative and regulatory solutions that strengthen the nation's supply chain by incentivizing the development and use of advanced and continuous manufacturing technology for critical drugs and active pharmaceutical ingredients, including support for advanced manufacturing grant appropriations. Further, it recommends that these technologies be adopted and implemented in both domestic and foreign manufacturing facilities.

Improve the function and composition of the Strategic National Stockpile. The pandemic highlighted weaknesses in the supply chain, including difficulty accessing the Strategic National Stockpile, as well as deficiencies in the medications and devices included in the stockpile. The group recommends regulatory and legislative actions that improve the function, composition and accessibility of the stockpile during public health emergencies.

Improve multinational cooperation on supply chain resilience. It recommends regulatory and legislative actions that increase the overall resilience of the United States supply chain by enhancing international cooperation and collaboration with foreign supply chain partners, including but not limited to foreign governments and manufacturers.

Incentivize quality and resilience. The group recommends regulatory and legislative action that creates incentives for manufacturers to improve drug and device manufacturing quality. It also recommends that policy solutions focus on outcomes that improve the overall resilience of the nation's medication and device supply chains.

Replicate asks for critical drug manufacturing transparency and oversight for medical devices and ancillary supplies. The CARES Act of 2020 included drug manufacturing provisions designed to mitigate and reduce drug shortages. The group recommends legislative and regulatory action to extend similar provisions to the manufacturing of medical devices and enhance reporting requirements for device manufacturers.